BRPI0815948A2 - "compostos heterocíclicos como antagonistas de receptorncrth2" - Google Patents

"compostos heterocíclicos como antagonistas de receptorncrth2"

Info

Publication number: BRPI0815948A2
Authority: BR; Brazil
Prior art keywords: antagonists; heterocyclic compounds; heterocyclic; compounds
Prior art date: 2007-10-10

Application number

BRPI0815948A

Other languages

English (en)

Inventor

Yuan W Wei

Original Assignee

Chemietek Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-10

Filing date

2008-10-09

Publication date

2019-09-24

2008-10-09 Application filed by Chemietek Llc filed Critical Chemietek Llc

2019-09-24 Publication of BRPI0815948A2 publication Critical patent/BRPI0815948A2/pt

Links

239000005557 antagonist Substances 0.000 title 1
150000002391 heterocyclic compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0815948A 2007-10-10 2008-10-09 "compostos heterocíclicos como antagonistas de receptorncrth2" BRPI0815948A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99829807P	2007-10-10	2007-10-10
PCT/US2008/079303 WO2009049021A1 (en)	2007-10-10	2008-10-09	Heterocyclic compounds as crth2 receptor antagonists

Publications (1)

Publication Number	Publication Date
BRPI0815948A2 true BRPI0815948A2 (pt)	2019-09-24

Family

ID=40549546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815948A BRPI0815948A2 (pt)	2007-10-10	2008-10-09	"compostos heterocíclicos como antagonistas de receptorncrth2"

Country Status (12)

Country	Link
US (1)	US8772312B2 (pt)
EP (1)	EP2197438B1 (pt)
JP (2)	JP2011500584A (pt)
KR (2)	KR20130069840A (pt)
CN (1)	CN101896178B (pt)
AU (1)	AU2008310874B2 (pt)
BR (1)	BRPI0815948A2 (pt)
CA (1)	CA2700824C (pt)
ES (1)	ES2548577T3 (pt)
IL (1)	IL204823A0 (pt)
RU (1)	RU2451019C2 (pt)
WO (1)	WO2009049021A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2300425A4 (en)	2008-06-24	2012-03-21	Panmira Pharmaceuticals Llc	PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
WO2010031183A1 (en)	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Indole derivatives as crth2 receptor antagonists
WO2010031184A1 (en) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Azaindole derivatives as crth2 receptor antagonists
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
SG176628A1 (en)	2009-06-05	2012-01-30	Link Medicine Corp	Aminopyrrolidinone derivatives and uses thereof
MX2012010820A (es)	2010-03-22	2012-10-10	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012107364A1 (en) *	2011-02-07	2012-08-16	Scipharm Sàrl	Novel composition for the treatment of cystic fibrosis
WO2012140612A1 (en)	2011-04-14	2012-10-18	Actelion Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
PH12016501764B1 (en)	2014-03-17	2024-05-17	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP6770522B2 (ja) *	2015-02-13	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
WO2017005759A1 (en) *	2015-07-07	2017-01-12	Intervet International B.V.	A process to make azaindole derivatives
WO2017005764A1 (en) *	2015-07-07	2017-01-12	Intervet International B.V.	A process to make tricycloketone intermediates of crth2 antagonists
WO2017046125A1 (en)	2015-09-15	2017-03-23	Actelion Pharmaceuticals Ltd	Crystalline forms
PT3356329T (pt) *	2015-09-29	2020-07-15	Novartis Ag	Processo para a preparação de ácido 1-(4-metanossulfonil-2-trifluorometil-benzil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético
JOP20190223A1 (ar) *	2017-04-01	2019-09-26	Novartis Ag	عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
CN113382995A (zh) *	2019-01-10	2021-09-10	石药集团中奇制药技术（石家庄）有限公司	作为crth2受体拮抗剂的杂环化合物的晶型
WO2020143793A1 (zh)	2019-01-10	2020-07-16	石药集团中奇制药技术（石家庄）有限公司	杂环化合物盐及其应用
CN114502164B (zh) *	2019-05-22	2024-01-26	石药集团中奇制药技术（石家庄）有限公司	杂环化合物及其盐的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60215000T2 (de) *	2001-05-23	2007-08-09	Merck Frosst Canada & Co, Kirkland	Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
CN1732171A (zh) *	2002-10-30	2006-02-08	麦克弗罗斯特(加拿大)公司	吡啶并吡咯里嗪和吡啶并吲嗪衍生物
EP1558614B1 (en) *	2002-10-30	2010-09-01	Merck Frosst Canada Ltd.	Pyridopyrrolizine and pyridoindolizine derivatives
JP4051398B2 (ja) *	2004-03-11	2008-02-20	アクテリオンファマシューティカルズリミテッド	テトラヒドロピリドインドール誘導体
JP4708885B2 (ja) *	2005-07-06	2011-06-22	日本電気株式会社	符号化装置、携帯端末装置及びそれらに用いる画素色情報符号化方法
US7696222B2 (en) *	2005-08-12	2010-04-13	Merck Frosst Canada Ltd	Indole derivatives as CRTH2 receptor antagonists
US20110112134A1 (en)	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors

2008
- 2008-10-09 US US12/681,356 patent/US8772312B2/en not_active Expired - Fee Related
- 2008-10-09 KR KR1020137011440A patent/KR20130069840A/ko not_active Ceased
- 2008-10-09 ES ES08838211.4T patent/ES2548577T3/es active Active
- 2008-10-09 EP EP08838211.4A patent/EP2197438B1/en active Active
- 2008-10-09 RU RU2010117156/04A patent/RU2451019C2/ru active
- 2008-10-09 CA CA2700824A patent/CA2700824C/en active Active
- 2008-10-09 WO PCT/US2008/079303 patent/WO2009049021A1/en not_active Ceased
- 2008-10-09 JP JP2010529022A patent/JP2011500584A/ja active Pending
- 2008-10-09 KR KR1020107010092A patent/KR101442663B1/ko not_active Expired - Fee Related
- 2008-10-09 CN CN2008801092963A patent/CN101896178B/zh active Active
- 2008-10-09 AU AU2008310874A patent/AU2008310874B2/en not_active Ceased
- 2008-10-09 BR BRPI0815948A patent/BRPI0815948A2/pt not_active IP Right Cessation
2010
- 2010-03-28 IL IL204823A patent/IL204823A0/en unknown
2013
- 2013-06-19 JP JP2013128863A patent/JP5680146B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2700824A1 (en)	2009-04-16
JP2013209425A (ja)	2013-10-10
HK1147674A1 (en)	2011-08-19
CA2700824C (en)	2013-12-10
CN101896178A (zh)	2010-11-24
EP2197438A4 (en)	2011-10-12
WO2009049021A1 (en)	2009-04-16
AU2008310874B2 (en)	2012-03-15
RU2451019C2 (ru)	2012-05-20
IL204823A0 (en)	2010-11-30
KR20100065398A (ko)	2010-06-16
CN101896178B (zh)	2013-11-20
EP2197438A1 (en)	2010-06-23
US8772312B2 (en)	2014-07-08
KR101442663B1 (ko)	2014-09-22
KR20130069840A (ko)	2013-06-26
JP5680146B2 (ja)	2015-03-04
RU2010117156A (ru)	2011-11-20
JP2011500584A (ja)	2011-01-06
AU2008310874A1 (en)	2009-04-16
ES2548577T3 (es)	2015-10-19
US20100222270A1 (en)	2010-09-02
EP2197438B1 (en)	2015-07-15

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0718266A2 (pt)	2014-01-07	Compostos heterocíclicos como agentes anti-inflamatórios.
BRPI0717937A2 (pt)	2013-12-03	Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0910229A2 (pt)	2015-09-01	Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0922904A2 (pt)	2018-05-29	"compostos"
BRPI0814426A2 (pt)	2015-01-06	Compostos heterocíclicos úteis como inibidores de mk2
DE602008003015D1 (de)	2010-11-25	Heterocyclische spiroverbindungen
BRPI0813768A2 (pt)	2014-12-30	Derivados de benzazepina úteis como antagonistas de vasopressina
BRPI0916218A2 (pt)	2017-10-10	compostos heterocíclicos como composições praguicidas
BRPI0810462A2 (pt)	2014-10-14	Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0916233A2 (pt)	2018-03-13	compostos heterocíclicos antivirais
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
BRPI1015540A2 (pt)	2019-09-24	''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
BRPI0811280A2 (pt)	2015-01-20	Compostos amino-heterocíclicos
BRPI0718509A2 (pt)	2015-09-29	compostos orgânicos heterocíclicos
BRPI0718494A2 (pt)	2014-01-21	Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
ATE502948T1 (de)	2011-04-15	Substituierte bicyclolactamverbindungen
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
BRPI0918045A2 (pt)	2015-12-01	compostos de carboxamida heterocíclicos
BR112012003701A2 (pt)	2019-09-24	"novos antagonistas de quinolina-hepcidina"
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
BRPI0909157A2 (pt)	2015-11-24	compostos heterocíclicos como antagonistas de receptores de adenosina
HRP20151108T1 (xx)	2015-11-20	Antagonisti nogo-receptora
BRPI1007878A2 (pt)	2015-09-01	"compostos inseticidas"
BRPI0821349A2 (pt)	2019-09-24	compostos antivirais heterocíclicos
BRPI0817061A2 (pt)	2015-03-24	Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3